Ulf Jungnelius

Biography

Ulf’s past experience includes leading positions within oncology and clinical development at Celgene, Takeda, Pfizer and Eli Lilly. He has played key roles in the clinical development and regulatory approval process of blockbusters Gemzar® (gemcitabine) and Evista® (raloxifene). Key contributions to the clinical development of pharmaceuticals such as Alimta® (pemetrexed), Revlimid® (lenalidomide) and Vidaza® (azacitidine) are also a part of Ulf’s track record. In addition, he has led major Due Diligence processes which have resulted in multibillion dollar acquisitions, including Celgene’s acquisitions of Abraxis and Pharmion. Position: Director / Board Member Elected: 2010 Year of birth: 1951 Holdings*: 0 shares and 100 000 warrants Independent in relation to the company and its management: Yes Independent in relation to larger shareholders: Yes *Own or related natural or legal person holding shares and other financial instruments in the company

Research Interest

Ulf’s past experience includes leading positions within oncology and clinical development at Celgene, Takeda, Pfizer and Eli Lilly. He has played key roles in the clinical development and regulatory approval process of blockbusters Gemzar® (gemcitabine) and Evista® (raloxifene). Key contributions to the clinical development of pharmaceuticals such as Alimta® (pemetrexed), Revlimid® (lenalidomide) and Vidaza® (azacitidine) are also a part of Ulf’s track record. In addition, he has led major Due Diligence processes which have resulted in multibillion dollar acquisitions, including Celgene’s acquisitions of Abraxis and Pharmion.